212 related articles for article (PubMed ID: 29672827)
1. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.
Federico M; Bellei M; Marcheselli L; Schwartz M; Manni M; Tarantino V; Pileri S; Ko YH; Cabrera ME; Horwitz S; Kim WS; Shustov A; Foss FM; Nagler A; Carson K; Pinter-Brown LC; Montoto S; Spina M; Feldman TA; Lechowicz MJ; Smith SM; Lansigan F; Gabus R; Vose JM; Advani RH;
Br J Haematol; 2018 Jun; 181(6):760-769. PubMed ID: 29672827
[TBL] [Abstract][Full Text] [Related]
2. A lower ALC/AMC ratio is associated with poor prognosis of peripheral T-cell lymphoma-not otherwise specified.
Li Q; Gao S; Ma J; Liu S; Yue Y; Chen L; Li H; Wang X; Li D; Cao Z; Zhao Z; Wang X; Yu Y; Zhang Y; Wang Y
Leuk Res; 2018 Oct; 73():5-11. PubMed ID: 30172956
[TBL] [Abstract][Full Text] [Related]
3. Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma.
Kato A; Imai Y; Aoki K; Tabata S; Matsushita A; Hashimoto H; Takahashi T; Ishikawa T
Ann Hematol; 2014 Jul; 93(7):1185-91. PubMed ID: 24526138
[TBL] [Abstract][Full Text] [Related]
4. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy.
Chihara D; Oki Y; Ine S; Yamamoto K; Kato H; Taji H; Kagami Y; Yatabe Y; Nakamura S; Morishima Y
Leuk Lymphoma; 2009 Dec; 50(12):1999-2004. PubMed ID: 19860627
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous peripheral T-cell lymphoma, not otherwise specified: A single-center prognostic analysis.
Tolkachjov SN; Weenig RH; Comfere NI
J Am Acad Dermatol; 2016 Nov; 75(5):992-999. PubMed ID: 27498959
[TBL] [Abstract][Full Text] [Related]
6. Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database.
Bhatt VR; Giri S; Verma V; Manandhar S; Pathak R; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):373-8. PubMed ID: 27349764
[TBL] [Abstract][Full Text] [Related]
7. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
[TBL] [Abstract][Full Text] [Related]
8. Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma.
Yamasaki S; Yoshida S; Kato K; Choi I; Imamura Y; Kohno K; Henzan H; Tanimoto K; Ogawa R; Suehiro Y; Miyamoto T; Eto T; Ohshima K; Akashi K; Iwasaki H;
Int J Hematol; 2020 Jul; 112(1):74-83. PubMed ID: 32297159
[TBL] [Abstract][Full Text] [Related]
9. Peripheral T-cell lymphoma--not otherwise specified.
Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specified.
Shibata Y; Hara T; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Goto N; Nannya Y; Ito H; Kito Y; Miyazaki T; Takeuchi T; Saito K; Seishima M; Takami T; Moriwaki H; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Dec; 35(4):637-644. PubMed ID: 27338762
[TBL] [Abstract][Full Text] [Related]
11. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores.
Huh SJ; Oh SY; Lee S; Lee JH; Kim SH; Lee GW; Kim SJ; Kim WS; Lee HS; Jo JC; Kim MJ; Kwon JH; Kim HJ
Int J Hematol; 2019 Oct; 110(4):438-446. PubMed ID: 31250282
[TBL] [Abstract][Full Text] [Related]
12. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
[TBL] [Abstract][Full Text] [Related]
13. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
14. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Hosing C; Nieto YL; Oki Y
Br J Haematol; 2017 Mar; 176(5):750-758. PubMed ID: 27983760
[TBL] [Abstract][Full Text] [Related]
15. A retrospective clinical analysis of Japanese patients with peripheral T-cell lymphoma not otherwise specified: Hokkaido Hematology Study Group.
Torimoto Y; Sato K; Ikuta K; Hayashi T; Hirayama Y; Inamura J; Kobayashi H; Kobayashi R; Koda K; Kurosawa M; Mori A; Ota S; Sakai H; Shigematsu A; Shindo M; Shinzaki H; Takahashi F; Takimoto R; Tanaka J; Yamamoto S; Kohgo Y; Fukuhara T
Int J Hematol; 2013 Aug; 98(2):171-8. PubMed ID: 23813410
[TBL] [Abstract][Full Text] [Related]
16. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
[TBL] [Abstract][Full Text] [Related]
18. Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients.
Chen NC; Chang H; Kuo MC; Lin TL; Shih LY; Chuang WY; Kao HW
J Formos Med Assoc; 2024 Feb; 123(2):188-197. PubMed ID: 37558588
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of serum β2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified.
Kim HD; Cho H; Sohn BS; Park CS; Huh J; Ryu JS; Lee SW; Yoon SE; Kim SJ; Ko YH; Kim WS; Suh C
Leuk Lymphoma; 2022 Jan; 63(1):124-130. PubMed ID: 34702115
[TBL] [Abstract][Full Text] [Related]
20. Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients.
Xu P; Yu D; Wang L; Shen Y; Shen Z; Zhao W
Ann Hematol; 2015 Feb; 94(2):239-47. PubMed ID: 25193354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
